Prior to November 2020, there were no US Food and Drug Administration-authorized products for outpatient coronavirus disease 2019 (COVID-19) prevention or treatment. There have been surges in prescriptions for products (such as hydroxychloroquine1) proposed to treat COVID-19, but only approved for other conditions. We sought to determine if outpatient retail dispensing frequency of proposed treatments for COVID-19 increased since the March 13, 2020, declaration of a national emergency due to COVID-19.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: January 27, 2021.
Published Online: February 11, 2021. doi:10.1001/jamainternmed.2021.0299
Corresponding Author: Andrew I. Geller, MD, CDC COVID-19 Response Team, National Center for Emerging and Zoonotic Infectious Diseases, Division of Healthcare Quality Promotion, CDC, 1600 Clifton Rd NE, Mailstop V18-4, Atlanta, GA 30329 (email@example.com).
Author Contributions: Dr Geller had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Geller, Lovegrove, Budnitz.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Geller.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Lovegrove.
Obtained funding: Budnitz.
Administrative, technical, or material support: Geller, Lovegrove, Lind.
Supervision: Datta, Budnitz.
Conflict of Interest Disclosures: None reported.
Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.